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Introduction
Extracellular purine and pyrimidine nucleotides are
primordial molecules that serve multiple biological 
processes [1]. They are responsible for transmission
of genetic information, provide currency units for bio-
logical energy transfer, and are also released from
cells to provide integral elements of extracellular sig-
nalling. Within such 'purinergic' system, specificity
and regulation is dictated by the source of extracellu-
lar nucleotides and by the expression of specific
receptors on target cells: the P2 receptors.
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Abstract
We previously showed that the human heart expresses all known P2X and P2Y receptors activated by extra-
cellular adenine or uracil nucleotides. Despite evidence that, both in humans and rodents, plasma levels of
ATP and UTP markedly increase during myocardial infarction, the differential effects mediated by the various
adenine- and uracil-preferring myocardial P2 receptors are still largely unknown. Here, we studied the effects
of adenine and uracil nucleotides on murine HL-1 cardiomyocytes. RT-PCR analysis showed that HL-1 car-
diomyocytes express all known P2X receptors (except for P2X2), as well as the P2Y2,4,6,14 subtypes.
Exposure of cardiomyocytes to adenine nucleotides (ATP, ADP or BzATP) induced apoptosis and necrosis,
as determined by flow-cytometry. Cell death was exacerbated by tumour necrosis factor (TNF)-, a cytokine
implicated in chronic heart failure progression. Conversely, uracil nucleotides (UTP, UDP and UDPglucose)
had no effect 'per se', but fully counteracted the deleterious effects induced by adenine nucleotides and TNF-,
even if added to cardiomyocytes after beginning exposure to these cell death-inducing agents. Thus, expo-
sure of cardiomyocytes to elevated concentrations of ATP or ADP in the presence of TNF- contributes to
cell death, an effect which is counteracted by uracil-preferring P2 receptors. Cardiomyocytes do not need to
be 'primed' by uracil nucleotides to become insensitive to adenine nucleotides-induced death, suggesting the
existence of a possible 'therapeutic' window for uracil nucleotides-mediated protection. Thus, release of UTP
during cardiac ischaemia and in chronic heart failure may protect against myocardial damage, setting the
basis for developing novel cardioprotective agents that specifically target uracil-preferring P2Y receptors.
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Two distinct families of P2 receptors are currently
recognized: the ligand-gated P2X receptors, and the
G protein-coupled P2Y receptors [2–5]. So far, seven
distinct P2X receptor subtypes (P2X1–7) and eight
P2Y receptors (the P2Y1,2,4,6,11,12,13,14 subtypes)
have been cloned and characterized (ibidem).
Recently, a new putative member of the P2Y recep-
tor family, previously known as the 'orphan' receptor
GPR17, has been identified [6]. P2X receptors can
form homomeric and heteromeric channels allowing
Na+ and Ca2+ influxes, and have been implicated in
fast excitatory transmission [4] and, under some cir-
cumstances, in apoptotic cell death [7]. Conversely,
activation of metabotropic P2Y receptors leads to
modulation of adenylyl cyclase and/or phospholipase
C, depending upon the specific P2Y subtype [5, 8].
While P2X receptors primarily respond to adenine
nucleotides (i.e. ATP and ADP), P2Y receptors can
be further subdivided into (i ) the adenine-nucleotide-
preferring receptors (human and rodent P2Y1, P2Y12
and P2Y13, and human P2Y11), (ii ) the uracil-
nucleotide-preferring receptors, responding to either
UTP or UDP (human P2Y4 and P2Y6), (iii ) receptors
of mixed selectivity, which respond to both adenine
and uracil nucleotides (human and rodent P2Y2,
rodent P2Y4) and, (iv ) receptors responding solely to
sugar nucleotides, such as UDPglucose and
UDPgalactose (P2Y14) [5]. Interestingly, the newly
identified P2Y-like receptor (GPR17) is solely activated
by uracil nucleotides, with a pharmacological profile
which is intermediate between P2Y6 and P2Y14 [6].
Both P2X and P2Y receptors are widely distrib-
uted in human tissues and are known to mediate fun-
damental roles in the cardiovascular system [9]. At
myocardial level, despite very early reports on the
cardiac effects of adenine nucleotides and nucleo-
sides [10], and demonstration that ATP is released
from myocardial sympathetic terminals and hypoxic
cardiomyocytes [9], the effects mediated by specific
myocardial P2 receptors are just now beginning to be
elucidated. Adenine nucleotides induce rat cardiac
myocyte contraction possibly through P2X receptors,
and/or by increasing L-type Ca2+ currents (summa-
rized in [1]). Positive inotropism by ATP has been
also attributed to P2Y receptors [11]. Besides ade-
nine nucleotides, uracil nucleotides have been also
recently reported to act as positive inotropic agents
in rat and mouse cardiomyocytes [12,13]. The utiliza-
tion of stable selective agonists has allowed the
pharmacological characterization of the specific P2
receptors involved in the positive inotropic effects
induced by uracil nucleotides. Most important,
nucleotide plasma levels were measured to evaluate
whether UTP is released in patients with coronary
heart disease. Besides ATP, venous plasma levels of
UTP were increased (57%) in patients with myocar-
dial infarction, giving the first evidence for UTP
release in man. Based on these results, authors con-
cluded that extracellular pyrimidines (UTP and UDP)
could be important inotropic factors involved in the
development of chronic heart failure, a disease that
still remains a major cause of ill health in industrial
societies countries [14,15].
However, UTP may also play a significant role in
protecting the ischaemic heart against injury [16,17].
Short-term activation of UTP receptors indeed pro-
tects newborn rat cardiomyocytes against hypoxic
damage [16] and significantly reduces the cell death
caused by hypoxia via activation of P2Y2 and P2Y4
receptors [17].
Thus, besides influencing cardiac contractility, P2
receptors may also directly regulate the viability of
myocardial cells. In a recent study, we have shown
that the full repertoire of known P2X and P2Y recep-
tors is expressed in the human heart from both
healthy donors and patients with chronic heart failure
(CHF) undergoing cardiac transplantation [18]. We
also showed that the ionotropic P2X6 receptor was
up-regulated in CHF subjects, as confirmed by quan-
titative real time-PCR [18]. The potential significance
of this change was studied in primary cardiac fibrob-
lasts freshly isolated from young pigs. Exposure of
cardiac fibroblasts to ATP or its hydrolysis-resistant-
analogue benzoylATP (BzATP) induced apoptosis.
Tumour necrosis factor (TNF)- (a pro-inflammatory
cytokine implicated in CHF progression) [19] exacer-
bated cell death. In cardiac fibroblasts, exposure to
TNF- inhibited the down-regulation of P2X6 mRNA
induced by prolonged agonist exposure, suggesting
that, by preventing ATP-induced P2X6 desensitiza-
tion, TNF- may abolish a defence mechanism
meant at avoiding Ca2+ overload and, ultimately,
Ca2+-dependent cell death. This may provide a basis
for P2X6 up-regulation in CHF. Globally, these find-
ings suggest that the interaction between TNF- and
the up-regulated P2X6 receptor may represent a
novel pathogenic mechanism in CHF.
In the present study, based on our previous results
and on the demonstration that, besides ATP, UTP is
also released from the heart during cardiac ischaemia
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[12], we have investigated the effects of both adenine
and uracil nucleotides on the viability of HL-1 
cardiomyocytes, the only available cell line that 
spontaneously contracts in vitro and maintains a dif-
ferentiated cardiac phenotype [12]. In line with our
previous findings [20], we show that exposure of HL-
1 cardiomyocytes to ATP or ADP induces cell death
by both apoptosis and necrosis, an effect which was
increased by pre-treatment of cells with TNF-. On
the contrary, uracil nucleotides (UTP, UDP and
UDPglucose), utilized either alone or with TNF-, did
not induce apoptosis or necrosis ‘per se’, but signifi-
cantly reduced cardiomyocyte death induced by ade-
nine nucleotides. We conclude that activation of
uracil-preferring P2Y receptors in cardiomyocytes
counteracts the deleterious effects mediated by ATP
and TNF- on myocardial cells. We also suggest that
release of UTP during cardiac ischaemia and during
development of CHF may be protective against
myocardial damage. These findings may have impor-
tant therapeutic implications and set the basis for the
development of novel cardioprotective agents that
specifically target uracil-preferring P2Y receptors.
Materials and methods 
HL-1 cardiomyocytes
HL-1 cardiomyocytes were a kind gift of Professor W.C.
Claycomb, LSU Health Sciences Center, New Orleans, LA,
USA [20]. Cells were cultured in Complete Claycomb
Medium supplemented with 10% foetal calf serum (FCS)
(JRH Biosciences, UK) and Norepinephrine (100 M, Sigma-
Aldrich), following Professor Claycomb's instructions. Cells
were seeded in six-well plates at various densities
(48–100–200 x 103); on the next day, medium was replaced
and after 8 hrs, HL-1 cells were pre-treated overnight with
TNF- (10 ng/ml) followed by addition of ATP (25–500 µM) or
ADP (250–500 µM) or 3´-benzoyl adenosine 5´-triphosphate
(BzATP, 100 µM), adenosine 5´-O-(3-thiotriphosphate)
(ATPS, 500 µM), 2-methylthioadenosine 5´-triphosphate
(2MeSATP, 500 µM) and 2-methylthioadenosine 5´-diphos-
phate (2MeSADP, 500 µM) (Sigma-Aldrich). Uracil
nucleotides (UTP, UDP, UDPglucose, 100 nM-500 µM,
Sigma-Aldrich) and all antagonists [8-cyclopentyl-1, 
3-dipropylxanthine (CPX 10 µM, Sigma-Aldrich), 5-amino-
7-(-phenylethyl)-2-(8-furyl)pyrazolo(4,3-epsilon)-1,2,
4-triazolo(1,5-c)pyrimidine (SCH58261, 100 nM, from
Schering-Plough), 9-chloro-2-(2-furyl)-5-phenylacety-
lamino(1,2,4)-triazolo(1,5-c)quinazoline (MRS1220, 100 nM,
Sigma-Aldrich), 2´deoxy-N6-methyl adenosine 3´,5´ diphos-
phate (MRS2179, 100 µM, Sigma-Aldrich), pyridoxal-phos-
phate-6-azophenyl-2´,4´-disulfonate (PPADS, 100 µM,
Sigma-Aldrich), suramin (100 µM, Sigma-Aldrich), reactive
blue 2 (RB2, 100 µM, Sigma-Aldrich) and Cangrelor (10 µM,
The Medicines Company, Parsippany, NJ, USA)] were all
added to cultures 30 min before adenine nucleotides. In
selected experiments, 24 hrs after seeding, medium was
replaced with Claycomb medium without FCS and
Norepinephrine, followed by addition of TNF- and ade-
nine/uracil nucleotides. In these experiments, after phar-
macological treatments cells were maintained in Claycomb
medium without serum and norepinephrine; under these
conditions, cells are more sensitive to cell death and there-
fore ATP was used at lower concentration (100 µM).
Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
Extraction of total RNA and RT-PCR were performed as
described [18], Control samples lacking reverse transcrip-
tase were processed in parallel. All reagents were from
Invitrogen (Milan, Italy). Amplifications were performed in a
GeneAmp 9700 thermal cycler (Applied Biosystems) using
primers designed with Oligo4 (see Table 1), as described [18].
For the expression profile of P2 receptors the following
murine positive controls were used: trigeminal ganglia for
P2X2 and P2X3, total brain for P2X1, P2X4, P2X5, P2X7,
P2Y13 and P2Y14, heart for P2X6, liver for P2Y4, lung for
P2Y2 and N9 cells for P2Y1, P2Y6 and P2Y12 [8, 21, 22].
Nuclear staining of adhering cells
After 24 hrs in culture, cells were fixed in 4% paraformalde-
hyde in PBS and nuclear chromatin stained by using the
fluorescent dye Hoechst 33258 (Società Italiana Chimici),
as described [23].
Flow cytometric evaluation of apoptosis
The percentage of apoptotic and necrotic cells in the total
population (adhering+detached cells) was evaluated by
means of hypotonic propidium iodide (PI) staining of DNA
followed by flow cytometric analysis as described [18, 24,
25]. When utilized under hypotonic conditions, PI enters all
cells and allows a direct measure of DNA fragmentation and
of the ongoing cell death process. In selected experiments,
induction of apoptosis was also confirmed by measuring
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Annexin V binding to the outer membrane of apoptotic
cells; in these experiments, isotonic PI was used in paral-
lel, as described [25]. When employed at isotonic condi-
tions, PI can indeed only permeate cells with damaged
membranes, thus providing a direct measure of earlier
membrane events associated to necrosis (ibidem).
Statistical analysis
All results are expressed as mean ± S.E.M. of three inde-
pendent experiments. Statistical significance between
groups was derived from one-way-ANOVA followed by
Scheffe's F-test. A P value less than 0.05 was considered
significant.
Results
HL-1 cardiomyocytes express 
P2 receptors responding to both 
adenine and uracil nucleotides 
As a first step to the characterization of the effects of
P2 receptors on the viability of HL-1 cells, we
assessed the presence of all rodent P2 receptors by
RT-PCR. Amplification products with the expected
molecular weight for all known P2X receptors (with
the only exception of P2X2) and for P2Y2, P2Y4,
P2Y6 and P2Y14 were obtained (Fig. 1). No specific
Table 1. RT-PCR primers for murine P2X and P2Y receptors: sequences, annealing temperatures, accession number
and expected amplification product lengths
P2X and P2Y primers TA (°C) Accession number cDNA (bp)
P2X1 S 5´-GTTTGGGATTCGCTTTGA-3´
A 5´-TCAGGAAGGGAAGTGTGG-3´
55.8 NM_008771 452
P2X2 S 5´-GGTGGAGGATGGGACTTC-3´
A 5´-ATGGTGGGAATGAGACTG-3´
53.1 Y10473, AB094664,
AB094663
498
P2X3 S 5´-ACTTTGTGGGGTGGGTTT-3´
A 5´-GCTGCCATTCTCCATCTT-3´
55.6 NM_145526 767
P2X4 S 5´-GGAATTGGGACTGGAAGG-3´
A 5´-GGAGTGGAGACCGAGTGA-3´
55.8 NM_011026 774
P2X5 S 5´-CCAATCTCTACTGCCCCATC-3´
A 5´-TGTCTCGGTAAAACTCGC-3´
54.2 NM_033321 438
P2X6 S 5´-GCTCAAGTCCAGGGCAGATG-3´
A 5´-CAGTCAGAGCCTTTCGTGTCC-3´
57.7 NM_0011028 482
P2X7 S 5´-GGCATCCGTTTTGACATC-3´
A 5´-CTGGGGTCTTGGAACTTC-3´
54 NM_0011027 360
P2Y1 S 5´-CCTGCGAAGTTATTTCATCTA-3´
A 5´-GTTGAGACTTGCTAGACCTCT-3
51.6 NM_008772 319
P2Y2 S 5´-GCAGCATCCTCTTCCTCACCT-3´
A 5´-CATGTTGATGGCGTTGAGGGT-3´
60.2 NM_008773 503
P2Y4 S 5´-CTTTGGCTTTCCCTTCTTGA-3´
A 5´-GTCCGCCCACCTGCTGATGC-3´
56.5 NM_020621 427
P2Y6 S 5´-CGCTTCCTCTTCTATGCCAA-3´
A 5´-GTAGGCTGTCTTGGTGATGTG-3´
59.6 AF298899 480
P2Y12 S 5´-CCGCTACCTGAAGACCACCA-3´
A 5´-GTTCGCCACCTTCTTGTCCTT-3´
55.1 NM_027571 641
P2Y13 S 5´-CAGGGACACTCGGATGACA-3´
A 5´-CACCGCATAAAACAGAAGC-3´
55.4 NM_028808 577
P2Y14 S 5´-GTCTCTGCCGTCATCTTCT-3´
A 5´-GGGTCCAGACACACATTG-3´
54.3 NM_133200 591
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signals for P2Y1, P2Y12 and P2Y13 were obtained;
negative data were not due to technical problems,
since specific amplification products for these recep-
tors were detected in murine tissues or cell lines
which express these receptors [8, 21, 22] here uti-
lized as positive controls (Fig. 1).
Exposure of HL-1 cardiomyocytes 
to adenine nucleotides induces cell
death, which is exacerbated by TNF-
In line with our previous findings [18], a 24 hr-expo-
sure of HL-1 cardiomyocytes to ATP and to the rela-
tively-selective P2X agonist BzATP resulted in a dra-
matic reduction of the number of cells adhering to the
culture substrate (Fig. 2A). Cell number reduction by
ATP and BzATP was due to induction of cell death by
both apoptosis and necrosis, as shown by flow cyto-
metric analysis of PI-stained nuclei (Fig. 2B). In a
similar way to cardiac fibroblasts [18], the pro-inflam-
matory cytokine TNF- exerted little effect 'per se' on
the viability of HL-1 cardiomyocytes, but dramatically
potentiated the cell death induced by ATP, and, to a
lesser extent, by BzATP (Fig. 2B). To further confirm
that the cell death induced by adenine nucleotides is
indeed apoptosis, we evaluated another established
marker of apoptosis, that is, Annexin V binding to the
outer membrane of apoptotic cells, as previously
described [25]. Exposure to adenine nucleotides pro-
duced a significant increase in the percentage of
Annexin V (apoptotic)-positive cells, from about
8.00% in Control cultures to more than 35.00% after
exposure to ATP (Fig. 2C). With the latter method, in
the ATP+TNF- condition, apoptosis was 47.00%;
thus, potentiation of ATP-induced effects by TNF-
was less evident if compared to that observed at the
nuclear level with hypotonic PI (Fig. 2B). This could
be explained by hypothesising that TNF- is indeed
accelerating the progression of the ATP-induced cell
death program downstream the cell membrane. At a
membrane level, where apoptosis-induced changes
precede nuclear fragmentation, potentiation of ATP
effects by TNF- is less visible, since Annexin 
V-positive cells are still alive and will undergo cell
death at later time points.
Of a number of other adenine nucleotides tested,
only ADP and ATPS (but not 2MeSATP or
2MeSADP) were able to induce cardiomyocyte apop-
tosis and necrosis; also in this case, induction of cell
death was potentiated by TNF- (Fig. 3A).
Fig. 1 Murine HL-1 cardiomy-
ocytes express P2X1,3,4,5,6,7
and P2Y2,4,6,14. The pres-
ence of P2 receptors was
assessed using ad hoc
designed RT-PCR primers
for all cloned murine P2
receptors. For each recep-
tor, amplification products
in parallel with MW stan-
dards are reported. Various
tissues or cell lines were
analysed in parallel as a
positive controls: trigeminal
ganglia for P2X2 and P2X3,
total brain for P2X1, P2X4,
P2X5, P2X7, P2Y13 and
P2Y14, heart for P2X6, liver
for P2Y4, lung for P2Y2 and
N9 cells for P2Y1, P2Y6 and
P2Y12. No products were
detected in samples that
did not undergo retrotran-
scription (–).
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Adenine nucleotides-induced
cardiomyocyte death is mediated 
by activation of P2 receptors
To verify if the cell death effect reported above 
is actually due to activation of P2 receptors, HL-1
cardiomyocytes were exposed to ATP and TNF- in
the presence of various P2 receptor antagonists
such as Reactive Blue 2 (RB2), PPADS and suramin
[8, 26, 27]. Suramin was the most potent of the three
tested antagonists in inhibiting the nuclear signs of
apoptotic death induced by ATP and TNF-; a lower,
Fig. 2 Cardiomyocyte death
induced by ATP or BzATP alone
or in combination with TNF-.
After 24 hrs treatment with either
ATP (500 M) or the selective P2X-
agonist BzATP (100 µM), car-
diomyocytes were fixed, stained
with the Hoechst 33258 dye and
the number of adhering cells
evaluated by fluorescence
microscopy. Data are reported
as % of control cell number (A).
For evaluation of apoptosis and
necrosis (B), cells were exposed
to ATP or BzATP, alone or 
in combination with TNF-
(10ng/ml), as indicated. After 
24 hrs, cells were collected and
the percentage of apoptotic and
necrotic cells measured by flow
cytometric analysis of DNA 
fragmentation with Propidium
Iodide. Data represent the mean
± S.E.M. of three independent
experiments. *P<0.05 versus
control, (P<0.05 versus TNF-
alone, and §P<0.05 versus ATP
or BzATP alone, by one way
ANOVA (Scheffe's F test). (C)
Annexin V staining confirmed the
induction of apoptotic cell death.
Cells were exposed to ATP
alone or in combination with
TNF-, as previously described.
At the end of the incubation peri-
od, cells were collected, and
stained with Annexin V to detect
membrane signs of apoptotic
death. Blank refers to unstained
negative control cells, used to
calibrate the instrument. The
graph shows a representative
experiments (percentages of
Annexin V-positive cells: Control,
8.61%; ATP alone, 38.57%;
ATP+TNF-, 47.12%). Comparable
results were obtained in four
independent experiments.
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Fig. 3 Pharmacological characterization of adenine nucleotides-induced cardiomyocyte death. HL-1 cardiomyocytes
were exposed to either ADP, ATPS, 2MeSATP or 2MeSADP (all 500 M) for 24 hrs, alone or in combination with TNF-
 (10 ng/ml), as indicated (A), or to ATP (500 M) and TNF- (10 ng/ml), either alone or in combination with the P2
receptor antagonists RB2 or suramin, all utilized at a 100 M concentration (B). For suramin, the original traces of a
representative experiment are shown in C. The percentages of apoptotic and necrotic cells measured by flow cytomet-
ric analysis with hypotonic PI (A) or by Annexin V/isotonic PI (B) (see Materials and methods) are shown. In A and B,
data represent the mean ± S.E.M. of three and four independent experiments, respectively. *P<0.05 versus control. In
A, #P<0.05 versus TNF- and §P<0.05 versus corresponding adenine nucleotide alone, and in B §P<0.05 versus ATP
+ TNF-, by one way ANOVA (Scheffe's F test).
J. Cell. Mol. Med. Vol 12, No 2, 2008
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but statistically significant inhibition was observed
with PPADS and RB2 (Table 2). Also in this case, the
specificity of these effects was confirmed by the
Annexin V method. In these experiments, isotonic PI
(see Materials and methods) was used to measure
necrotic cell death in the same samples. Figure 3B
shows the results from four independent Annexin
V/isotonic PI experiments confirming the protective
effects of RB2 and suramin on both the apoptosis
(white bars) and the necrosis (black bars) induced by
ATP and TNF- (for suramin, the original traces 
of one representative experiment are shown in 
Fig. 3C). Basically, suramin and RB2 were equivalent
in reducing cell death at the membrane level, with
RB2 showing a little more pronounced effect.
Conversely, RB2 did not modify the cell death effects
mediated by the P2X agonist BzATP (data not
shown), suggesting that different P2 receptor sub-
types may be involved in the cell death induced by
different adenine nucleotides (see also below). We
also tested MRS2179 and cangrelor which act as
selective P2Y1 and P2Y12,13 receptor antagonists,
respectively [26]. In line with the lack of expression of
these three receptor subtypes (Fig. 1), none of these
antagonists had any effect on the cell death induced
by ATP and TNF- (data not shown). Upon addition
to cells, ATP is quickly degraded to adenosine, which
can then activate the P1 receptors (subdivided into
the A1, A2A, A2B and A3 subtypes [28]). Based on
previous data suggesting important functional effects
of these receptors in the cardiovascular system 
[29, 30], we next verified if P1 receptors could con-
tribute to the detected effects by utilizing specific P1
receptor antagonists. In our experimental model,
ATP-induced cytotoxicity was not counteracted by
either 8-cyclopentyl-1,3-dipropylxanthine (CPX, which
primarily antagonizes the A1 and A2B receptors
[31–33]), or by the selective A2A antagonist SCH58261,
or by the selective A3 antagonist MRS1220 [28] (data
not shown), thus ruling out a role for these receptors
in the detected effects.
As mentioned above, BzATP primarily behaves as
a P2X receptor-agonist [4], whereas ATP activates
both P2X and adenine-sensitive P2Y receptors [4].
Of the utilized P2 receptor antagonists, RB2 is rela-
tively ineffective at P2X receptors and primarily acts
as a P2Y4,6,11 antagonist, PPADS antagonises
P2X1,2,3,5 and P2Y4,6, whereas suramin effectively
blocks P2X1,2,3,5 and P2Y2,6,11 [4, 34]. On the basis
of the results reported above, we suggest that both
P2X and P2Y receptors mediate cardiomyocytic cell
death by adenine nucleotides. Based on the expres-
sion profile of P2 receptors in HL-1 cells (Fig. 1), we
also suggest that, among P2Y receptors,
P2Y2/P2Y4, are the most likely candidates for induc-
tion of cell death. Among P2X receptors, P2X1 and
P2X5 which are antagonised by both suramin and
PPADS, may be involved in cell death induction; how-
ever, since P2X receptors can form heteromers char-
acterized by different and unpredictable pharmaco-
logical profiles [4], in this case, a definite conclusion
regarding the specific receptor subtypes involved
cannot be drawn.
Uracil nucleotides do not affect 
cardiomyocytic viability and 
protect against cell death induced 
by adenine nucleotides 
Since several of the P2Y receptors expressed by HL-1
cardiomyocytes also respond to uracil nucleotides
(i.e. P2Y2, P2Y4, P2Y6 and P2Y14, Fig. 1), the effects
of uracil agonists on HL-1 cardiomyocytes were also
assessed. At variance from ATP, neither UTP (which
activates P2Y2 and P2Y4) nor UDP nor UDPglucose
(which activate the P2Y6 and P2Y14 receptor subtypes,
Table 2. Reduction of ATP+TNF--induced apoptotic
cell death by P2 receptor antagonists
Apoptosis (% of ATP+TNF-
set to 100% ± S.E.M.)
ATP+TNF- 100.00±5.64
+ Suramin (100 µM) 33.52±6.85*
+ PPADS (100 µM) 49.3±2.1*§
+ RB2 (100 µM) 42.11±7.69*§
Murine cardiomyocytes were exposed to ATP (500 µM) in combi-
nation with TNF- (10 ng/ml), together with the various P2 recep-
tor antagonists (which were added 30 min before). At the end of
the incubation period, the percentage of apoptotic death was
evaluated by isotonic PI staining of nuclei (see Materials and
methods), followed by flow cytometric analysis. ATP+TNF--
induced apoptosis was set to 100 %. The three antagonists had
no effect on cell survival when utilized alone (data not shown).
Data represent the mean ± S.E.M of three independent experi-
ments. *P<0.05 versus ATP+TNF-, and §P<0.05 versus control,
by one-way ANOVA (Scheffe’s F test).
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respectively [34]), had any effect ‘per se’ on the via-
bility of HL-1 cardiomyocytes, not even when
assayed in presence of TNF- (Fig. 4A). We then
tested the possible effect of these ligands on adenine
nucleotides-induced death. In a first set of experi-
ments, uracil nucleotides were added to cells 30 min
before addition of either ATP alone or ATP+TNF-.
As expected, exposure of HL-1 cardiomyocytes to
ATP and TNF- for 24 hrs resulted in dramatic cyto-
toxicity (see micrograph in Fig. 4C) and in highly sig-
nificant induction of both necrosis and apoptosis (see
cytogram in Fig. 4C) with respect to control healthy
cells (Fig. 4B). Addition of either UDP (Fig. 4D), or
UTP or UDPglucose (Fig. 4E) fully reversed cell
death induced by ATP+TNF-. As an example, in the
experiment reported in Figure 4E, the number of
necrotic and apoptotic cells in the ATP+TNF- group
was reduced from 22.8% and 28.8% to 6.5% and
6.2%, respectively, upon addition of UDPglucose.
Results were fully confirmed also by evaluating
Annexin V staining of apoptotic cells (Fig. 4F). Here
again, Annexin V binding induced by ATP+TNF-
was prevented by UDP. A similar protective effect
was observed against ADP-induced cell death.
UDP significantly reduced both the apoptosis and
necrosis induced by either ADP alone, or by
ADP+TNF- (Fig. 4G).
Both adenine nucleotides-induced death (sum of
apoptosis and necrosis) and uracil nucleotides-medi-
ated cytoprotection are concentration-dependent
events. In particular, ATP displayed an EC50 value
(i.e. concentration eliciting 50% of maximal effect) of
99.68 µM and 91.41 µM in the absence and presence
of TNF-, respectively (Fig. 5A; Table 3); thus, poten-
tiation of cell death by TNF- seems mainly due to
increased effectiveness rather than to changes in the
potency of adenine nucleotides (see also Table 3).
Also the protective effects mediated by uracil
nucleotides were strictly concentration-dependent,
with IC50 values (i.e. concentrations needed to inhibit
50% of ATP-induced cell death) of 7.29 M, 10.64 M
and 2.76 M for UTP, UDP and UDPglucose, respec-
tively (Figs 5B–D; Table 3). This suggests a rank
order of potency of UDPglucose  UTP  UDP. A
comparable rank order of potency for uracil
nucleotides was obtained when the effects of UTP,
UDP and UDPglucose were analysed separately
against ATP-induced apoptosis or necrosis (data not
shown). All experiments above have been performed
by adding uracil nucleotides to cells 30 min before
adenine nucleotides. We next tested the time-
dependence of uracil nucleotides-mediated protec-
tion. Addition of UDP together with (Fig. 6C) or 
30 min after ATP (Fig. 6D) still fully protected cells
against adenine nucleotide-induced death, suggest-
ing the existence of a possible 'therapeutic' window
for uracil nucleotides-mediated protection, and 
that cardiomyocytes do not need to be 'primed' by 
uracil nucleotides to become insensitive to ATP-
induced death.
Discussion
Here we demonstrate that adenine and uracil
nucleotides, which both in rodents [9, 35, 36], pig [37]
and man [9, 12] are released in the blood stream dur-
ing heart hypoxia, play strikingly different effects on
cardiomyocyte viability. The novelty of the present
results is twofold: first, we show a role for P2 recep-
tors (both P2X and adenine-preferring P2Y recep-
tors) in the cardiomyocyte death induced by adenine
nucleotides (an effect which is exacerbated by TNF-,
a well-established pathogenetic factor in cardiac dis-
ease development), and, second, we demonstrate
that uracil nucleotides fully protect against the dele-
terious effects mediated by adenine nucleotides and
TNF-. A combination of pharmacological and RT-
PCR studies suggests that several uracil-preferring
P2Y receptors expressed on cardiomyocytes likely
contribute to these pro-survival effects. These recep-
tors may thus represent new appropriate targets for
innovative drug therapies aimed at cardiac protection
during myocardial infarction and in CHF.
In the heart, hypoxic conditions induce ATP
release [35, 36]. Functionally, released ATP has been
involved in inotropy and hypertrophy of cardiomy-
ocytes [38], and, as more recently demonstrated, in
myocardial cell death (our previous data [18] and the
present results). All these effects are likely mediated
by the activation of specific P2 receptors on either
cardiomyocytes or fibroblasts. Here we show that
murine cardiomyocytes express a wide panel of P2X
and P2Y receptors known to either exclusively
respond to adenine nucleotides (P2X receptors), to
both adenine and uracil nucleotides (P2Y2, P2Y4,
P2Y6) or to sugar nucleotides (P2Y14 receptor). Such
a large heterogeneity of P2 receptor expression is
consistent with previous studies [18, 39–42], and 
suggests involvement of these receptors in multiple
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Fig. 4 Uracil nucleotides have no effect 'per se' on cardiomyocytic viability, but protect cells from ATP and ADP-induced
cytotoxicity. To assess the effect of uracil nucleotides on HL-1 cardiomyocytic viability, cells were exposed to UTP, UDP
or UDPglucose (500 µM) alone or in combination with TNF-, and apoptosis and necrosis determined after 24 hrs by
flow-cytometry. Parallel cultures were treated with ATP, here utilized as a positive control (A). The effect of TNF- alone
is shown in Figure 2B. *P < 0.05 versus corresponding Control, by one-way ANOVA (Scheffe's F test). To assess the abil-
ity of uracil nucleotides to counteract cardiomyocyte death induced by ATP+TNF-, cells were treated with either vehi-
cle (B), or ATP+TNF- (500 µM and 10 ng/ml, respectively) in the absence (C) or presence of UDP (100 µM, D), UTP
(25 µM) or UDPglucose (10 µM) (E). In these experiments, uracil nucleotides were added to cells 30 min before ade-
nine nucleotides. After 24 hrs, micrographs of adhering cells were taken (scale bar: 50 µm) and flow cytometric analy-
sis was performed on the total cell population. In cytograms, first and second numbers on the left represent the per-
centage of necrotic and apoptotic cells, respectively. Results from a typical experiment are shown in (B–E). Similar data
were obtained in five independent experiments. UDP similarly protected cells from the apoptosis and necrosis induced
by either ADP alone (500 µM) or ADP and TNF- (10 ng/ml) (F). Annexin V staining of cells confirmed the complete
protection exerted by uracil nucleotides. The percentages of Annexin V-positive cells in this representative experiment
(out of three) were: Control, 8.1%; UDP alone, 8.4%; ATP+TNF-, 56.4%; ATP+TNF-+UDP, 11.3%. (G) *P < 0.05 
versus corresponding Control, §P<0.05 versus ADP alone, #P < 0.05 versus ADP+TNF-, by one-way ANOVA
(Scheffe's F test); the mean values ± S.E.M. of four independent experiments are shown.
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functional effects. Specifically, our data suggest that
activation of P2 receptors by adenine nucleotides in
the presence of TNF- results in apoptosis and
necrosis. In a similar way to pig cardiac fibroblasts
[18], only modest effects on HL-1 cardiomyocytes
viability were detected when adenine nucleotides
and TNF- were utilized alone ([18] and the present
data), suggesting that a synergistic interaction
between ATP/ADP and TNF- is needed to induce
cell death. Effects induced by ATP and ADP are con-
centration-dependent, with EC50 values in the µMolar
range, which are consistent with the estimated
nucleotide concentrations at the cell surface during
cardiac ischaemia [12, 37], further confirming that the
effects reported here may bear a pathophysiological
significance. EC50 values for ATP and ADP in induc-
tion of cell death were not significantly altered by
TNF-, suggesting that the higher degree of cell
death observed in the presence of the cytokine is
likely due to increased effectiveness rather than
increased affinity of nucleotides towards their recep-
tors. Induction of cardiomyocyte apoptosis by ade-
nine nucleotides is a receptor-mediated event, as
also confirmed by data with the P2 receptor antago-
nists RB2, PPADS and suramin. Based on pharma-
cological data, we suggest that both P2X and P2Y
receptors may contribute to induction of cell death in
murine cardiomyocytes.
At variance from ATP, it is only recently that UTP
has been shown to be released during heart
ischaemia. The first demonstration was provided by
Erlinge and coworkers in a pig cardiac ischaemia in vivo
model [37]. UTP levels in the venous blood from the
cardiac vein increased according to a biphasic pat-
tern, with an increase 1 min after onset of cardiac
ischaemia, and a second increase 1 min after reperfusion.
Fig. 5 Concentration dependence of ATP-induced cardiomyocytic death (apoptosis+necrosis) and of uracil
nucleotides-mediated protection. HL-1 cardiomyocytes were exposed to graded concentrations of ATP (25–250 µM)
alone or in combination with TNF- (10 ng/ml, A). Cultures pre-treated with TNF- and incubated with 250 µM ATP
were exposed to graded (100 nM to 250 µM) concentrations of UTP (B), UDP (C), or UDPglucose (D). After 24 hrs,
the percentage of cell death was evaluated by cytofluorimetric analysis of PI stained nuclei. Data represent the mean
± S.E.M. of three independent experiments. Curves were calculated using GRAPH PAD Prism 4.0 software. EC50 val-
ues for induction of cell death by ATP or ATP+TNF- and IC50 values for uracil nucleotides protection are also shown
in individual panels and summarized in Table 3.
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In the same animals, total venous blood flow from the
heart and episodes of ventricular fibrillation or tachy-
cardia peaked at the same time points, suggesting
that nucleotide release positively correlated with both
cardiac blood flow and ventricular arrhythmia.
Importantly, release of UTP during myocardial infarc-
tion has been more recently confirmed also in man
[12].There still is little information regarding the source
of UTP release during heart ischaemia. Although both
myocytes, endothelial cells and platelets may theoret-
ically release uridine nucleotides into the blood
stream, the only published evidence for significant
release of UTP is from endothelial cells during
changes in flow (shear stress) [43]. Released UTP
may then act on myocardial P2 receptors; in line with
our previous findings [18], several uracil-preferring
P2Y receptors were indeed found by Wihlborg and
coworkers [12] in the human heart (P2Y2, P2Y4,
P2Y6). These receptors are also expressed in the
murine cardiomyocyte model utilized here, thus sup-
porting its validity for unveiling the functional roles of
these receptors in mammalian heart. In the Wihlborg
et al. study, UTP and UDP were also demonstrated
to mediate inotropic effects likely via P2Y6. On this
basis, and based on previous findings demonstrating
induction of vasoconstriction by UDP and UTP [44],
these authors proposed that uracil nucleotides may
play a similar role as angiotensin II in the develop-
ment of cardiac disease, and that, in a similar way to
angiotensin II receptor antagonists and angiotensin
converting enzyme inhibitors, selective antagonists
of UDP and UTP receptors may represent novel
agents in the treatment of hypertension and heart
failure via inhibition of peripheral resistance, inotropy
and cardiac hypertrophy. Our results instead suggest
that uracil nucleotides may also induce beneficial
effects on cardiomyocytes. Both UTP and UDP and
the sugar-nucleotide UDPglucose effectively counter-
acted cell death induced by adenine nucleotides and
TNF- on HL-1 cardiomyocytes. Protection by uracil
nucleotides is concentration-dependent, with striking-
ly low IC50 values (in the low µMolar range) against
ATP and ADP-induced cell death. Pharmacological
and expression data suggest that cardiomyocyte pro-
tection is mediated by multiple uracil-sensitive P2Y
receptors (P2Y2, P2Y4, P2Y6 and P2Y14; in this
respect, see also below).
The protective effects described here are consis-
tent with the previous demonstration that UTP pro-
tects neonatal rat cardiomyocytes against injury
induced by 120 min of hypoxia [16]. However, the
possible functional antagonism between uracil and
adenine nucleotides was not addressed in this study,
and only UTP, but not UDP, effectively protected car-
diomyocytes. P2Y2 and P2Y4 receptors, whose pres-
ence in neonatal cardiomyocytes was confirmed by
immunofluorescence staining and western blot, are
likely to mediate protection in this study, whereas a
role for P2Y6 was ruled out, based on the lack of
effect of UDP. This protection profile seems different
from that reported here, where all tested uracil
nucleotides were found to be protective. Moreover,
the effects described above [16] seems related to a
preconditioning mechanism, since cells needed to be
pre-exposed to UTP before hypoxia to show protec-
tion. Here, both UTP and other uracil nucleotides
were able to effectively protect cells even when added
after adenine nucleotides and TNF-. Strikingly, our
data suggest that the same receptors may even be
Table 3. Potency of adenine and uracil nucleotides in
regulation of HL-1 cardiomyocytes viability
Murine cardiomyocytes were exposed to graded concentrations
of either ATP alone (25–500 M), or ATP in the presence of the
cytokine TNF- (10 ng/ml), or UTP, UDP and UDP-glucose (100 M
to 250 M). In experiments where uracil nucleotides were chal-
lenged for their ability to inhibit the effects induced by adenine
nucleotides, an ATP concentration of 250 M in the presence of
10 ng/ml TNF- was utilized. In all  experiments, effects were
detected after 24 hrs. At the end of treatments, the percentage of
cell death (apoptosis+necrosis) was evaluated by cytofluorimet-
ric analysis of PI stained nuclei. Reported EC50 and IC50 values
refer to experiments shown in Fig. 5 (for more details, see Fig. 5
legend and text).
Nucleotide Type of effect EC50 or IC50 ±S.E.M.
ATP Induction of apoptosis
and necrosis 99.68±21.2 µM
ATP + TNF-
Induction of apoptosis
and necrosis 91.41±30.4 µM
UTP
Protection against cell
death induced by
ATP+TNF-
7.29±0.29 µM
UDP
Protection against cell
death induced by
ATP+TNF-
10.64±2.30 µM
UDPglucose
Protection against cell
death induced by
ATP+TNF-
2.76±0.49 µM
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involved in both cell death and cell protection. This
applies in particular to the HL-1 P2Y2 and P2Y4
receptors, that in rodents respond to both ATP and
UTP [8, 32]. It may be hypothesised that, depending
upon the identity of the nucleotide (adenine versus
uracil) binding to the receptor, different intracellular
pathways are activated, eventually leading to either
cell death (in the case of ATP) or cell protection (in
the case of UTP). Alternatively, when the receptor is
activated by one of its endogenous agonists 
(e.g. ATP) another agonist (UTP) can act as an
antagonist. This would not be unexpected for P2Y
receptors: for example, under specific conditions, the
agonist ATP can act as an antagonist at the ADP-
activated P2Y12 receptor subtype [8]. This interesting
issue will be investigated in HL-1 cardyomiocytes
future studies.
The protective effects of UTP have been also very
recently confirmed in rats upon induction of myocar-
dial infarction [17]. In animals injected with UTP 
30 min before infarction, the ratio of infarct size to
area at risk was significantly smaller with respect to
control untreated rats.
In conclusion, therapeutic targeting of pyrimidiner-
gic receptors may represent a novel promising strat-
egy for myocardial protection that certainly deserves
further exploration.
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